North Korea confirms 'successful' launch of ballistic missile

May 22, 2017

Seoul, May 22: North Korea today confirmed the "successful" launch of a medium-range ballistic missile, Pyongyang's state media reported, adding the weapon was now ready to be deployed for military action.

northkorea

State-run Korean Central News Agency said the North's leader Kim Jong-Un oversaw yesterday's missile test, which has sparked a fresh chorus of international condemnation and threats of tougher UN sanctions.

The missile tested was the Pukguksong-2, a land-based version of Pyongyang's submarine-launched weapon, using solid-fuel that allows for immediate firing, KCNA said.

"Saying with pride that the missile's rate of hits is very accurate and Pukguksong-2 is a successful strategic weapon, (Kim Jong-Un) approved the deployment of this weapon system for action," KCNA said.

"Now that its tactical and technical data met the requirements of the Party, this type of missile should be rapidly mass-produced in a serial way to arm the KPA Strategic Force," Kim said, referring to the North's army, according to the KCNA report.

The missile, which was described by Washington as medium-range, was fired from Pukchang in South Pyongan province and travelled about 500 kilometres (310 miles) before landing in the Sea of Japan, according to the South's armed forces.

KCNA said the test "aimed to finally verify all the technical indexes of the weapon system and thoroughly examine its adaptability under various battle conditions, before its deployment at military units for action."

The results of the test were "perfect", KCNA added.

The US, South Korea and Japan sharply denounced the launch and jointly requested an emergency meeting of the United Nations Security Council on the matter.

The launch came just one week after the North fired a Hwasong-12 intermediate-range missile, which according to Pyongyang flew almost 800 kilometres and was capable of carrying a "heavy" nuclear warhead.

Analysts said the Hwasong travelled further than any previous ballistic missile launched by the North.

The May 14 launch was seen as a significant step forward as the North accelerates efforts to develop an intercontinental ballistic missile (ICBM) capable of delivering a nuclear warhead to the continental United States.

The launches and a threatened sixth nuclear test have fuelled tension with the administration of US President Donald Trump, who has vowed that such an ICBM launch "won't happen."

He warned that no option is off the table in dealing with the North's weapons program, although Washington has so far opted for sanctions and diplomatic pressure, while looking to China, the North's closest ally, to help rein in Pyongyang.

Seoul's foreign ministry slammed the "reckless and irresponsible" firing as "throwing cold water on the hope and longing of the new government and the international community" for denuclearization and peace on the Korean peninsula.

South Korea's incoming left-leaning government has taken a more conciliatory line with Pyongyang than its conservative predecessors but has reacted strongly to the latest two missile tests.

Pyongyang has long had missiles that can reach targets across South Korea and Japan.

With an imputed range of 4,500 kilometres, the Hwasong-12 also puts US bases on the Pacific island of Guam within reach.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 2,2020

Jul 2: Democratic presidential candidate and former US vice-president Joe Biden has said that if he wins the November elections, strengthening the relationship with India which is America’s "natural partner", will be a high priority for his administration.

"India needs to be a partner in the region for our safety's sake and quite frankly for theirs," he said in response to a question on India-US relationship during a virtual fundraiser event on Wednesday.

At the fundraiser hosted by Chairman and CEO of Beacon Capital Partners Alan Leventhal, the former vice president said that India and the United States were natural partners.

"That partnership, a strategic partnership, is necessary and important in our security," Biden said when asked by an attendee whether India is critical to the US' national security.

Referring to his eight years as the vice president, he said, "In our administration, I was proud to play a role more than a decade ago in securing Congressional approval for the US-India Civil Nuclear Agreement, which is a big deal".

"Helping open the door to great progress in our relationship and strengthening our strategic partnership with India was a high priority in the Obama-Biden administration and will be a high priority if I'm elected president,” Biden said.

Both as the vice president and a senator from Delaware, he was a big supporter of India-US relationship.

About the November polls, Biden said that the character of the country is on the ballot. The upcoming election is the most important poll of a lifetime and that the country is currently engaged in a battle for its soul, he claimed.

Biden also slammed President Donald Trump and his administration over the handling of the coronavirus pandemic.

"Trump ignored warnings from the very beginning, refused to prepare and failed to protect the country. Not just now but throughout his presidency, undermining the very core pillars of ours, what I would argue, moral and economic strength.

"I really do believe that our country is crying out for leadership and maybe even more important, some healing. Today, we have an enormous opportunity not only to rebuild but to build back better than before. To build a better future. That's what America does," he added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 2,2020

Balochistan, May 1: Sajid Hussain, Editor-in-Chief of Balochistan Times, has been found dead in a Swedish town, the police have confirmed.

The Swedish police informed his family on Thursday night that they discovered his body from a river in Uppsala, The Times reported.
The Baloch journalist had been missing from the Swedish city since March 2 this year.

Sajid, 39, left Pakistan in 2012 and had been living as a refugee in Sweden since 2017. He wrote extensively on the suffering of the Balochis at the hands of the Pakistani military establishment.

His work often got him into trouble as the authorities did not like his reporting of Balochistan's forbidden stories, the reason he had to leave and live in exile.

The Baloch journalist was found dead two months after he went missing in Sweden.
Sajid left Pakistan because of security threats from Pakistan Army and its intelligence service ISI.

The spokesperson of the Baloch National Movement, Hammal Haider told news agency: "We are deeply saddened by the demise of prominent Baloch intellectual and writer Sajid Hussain."
"His death is indeed a loss of a great mind for the people of Balochistan. Due to his straightforwardness, he was loved among all journalistic, literary and political circles," added Haider.

"After this incident, we have serious concerns about our members and other Baloch refugees living in the West," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.